- Home
- SERA vs LCTX Comparison
SERA vs LCTX Comparison
Compare SERA & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERA
- LCTX
- Stock Information
- Founded
- SERA 2008
- LCTX 1990
- Country
- SERA United States
- LCTX United States
- Employees
- SERA N/A
- LCTX N/A
- Industry
- SERA Precision Instruments
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SERA Health Care
- LCTX Health Care
- Exchange
- SERA Nasdaq
- LCTX Nasdaq
- Market Cap
- SERA N/A
- LCTX 118.8M
- IPO Year
- SERA 2021
- LCTX N/A
- Fundamental
- Price
- SERA $3.43
- LCTX $0.41
- Analyst Decision
- SERA
- LCTX Strong Buy
- Analyst Count
- SERA 0
- LCTX 5
- Target Price
- SERA N/A
- LCTX $4.20
- AVG Volume (30 Days)
- SERA 103.1K
- LCTX 1.8M
- Earning Date
- SERA 03-19-2025
- LCTX 03-10-2025
- Dividend Yield
- SERA N/A
- LCTX N/A
- EPS Growth
- SERA N/A
- LCTX N/A
- EPS
- SERA N/A
- LCTX N/A
- Revenue
- SERA $77,000.00
- LCTX $9,499,000.00
- Revenue This Year
- SERA $4,536.36
- LCTX $25.10
- Revenue Next Year
- SERA $411.43
- LCTX $35.67
- P/E Ratio
- SERA N/A
- LCTX N/A
- Revenue Growth
- SERA N/A
- LCTX 6.19
- 52 Week Low
- SERA $3.33
- LCTX $0.40
- 52 Week High
- SERA $12.36
- LCTX $1.56
- Technical
- Relative Strength Index (RSI)
- SERA 32.89
- LCTX 26.71
- Support Level
- SERA $3.33
- LCTX $0.47
- Resistance Level
- SERA $4.20
- LCTX $0.55
- Average True Range (ATR)
- SERA 0.25
- LCTX 0.04
- MACD
- SERA -0.01
- LCTX -0.00
- Stochastic Oscillator
- SERA 10.99
- LCTX 8.18
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.